GABA-associated Depression and Insomnia

Published Online: Saturday, April 1, 2006

Most currently available sleep aids act at the benzodiazepine receptor site on the gamma-aminobutyric acidA (GABAA) receptor in the central nervous system (CNS). More than 90% of the GABAA receptors in the brain contain α12, or α3 subunits, also known as omega 1, 2, and 3 subunits. The α1-GABAA receptors are implicated in sedative/hypnotic and ataxic effects. The α2-GABAA receptors mediate anxiolytic and muscle-relaxant effects; the α3-GABAA receptors also mediate these effects in some cases, according to findings reported in the Proceedings of the National Academy of Sciences of the USA, January 2005, and the Journal of Pharmacology and Experimental Therapeutics, January 2002.

Sleep disorders, especially insomnia, are a frequent symptom of depression. There is considerable evidence that the neurotransmitter GABA is implicated in the biochemical pathophysiology of mood disorders, including anxiety and depression. Investigators conducted a study hoping to identify a variant of the α1-GABAA gene in patients institutionalized for a severe depressive disorder. Based on their findings, reported in Psychiatric Genetics (Winter 1998), the investigators concluded that the α1-GABAA receptor probably did not mediate GABA-associated depression.

Although the receptor site for GABA-associated depression remains to be identified, it may be the α2-GABAA or α3-GABAA subunit. The use of sedating antidepressants in patients with depression and comorbid insomnia is not supported by available evidence, according to findings reported in the Journal of Clinical Psychiatry, 2004. Because newer nonbenzodiazepine sleep aids act selectively at α1-GABAA receptors, a reasonable assumption is that conventional benzodiazepine sleep aids, which interact nonselectively with all 3 GABAA subunits in the CNS, may provide relief for patients who experience GABA-associated depression complicated by insomnia.




Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A